Market Overview

UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus

Related ONCY
Ophthotech Mega Million Deal With Novartis; Oncolytics Biotech Brain Cancer Trial Positive Data; Tarena International Solid Results
Oncolytics (ONCY) Enters Oversold Territory - Tale of the Tape

Stifel Nicolaus initiated its coverage on Oncolytics Ciotech (NASDAQ: ONCY) with a Buy rating and a price target of $6 a share.

Stifel Nicolaus commented, "We view ONCY's sole clinical candidate Reolysin as a compelling potential treatment for ~60% of cancers. Reolysin is a specific strain of a naturally occurring virus that only replicates in cancer cells with an activated Ras signaling pathway, a key metabolic pathway in cell metabolism that is mutated in over 60% of all carcinomas. Reolysin has demonstrated compelling efficacy in numerous oncology indications and as a live virus Reolysin's main side effect is "viral syndrome", not the typical side effects of chemotherapy."

Oncolytics Ciotech closed at $2.76 on Wednesday.

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ONCY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters